IP Library › Patent Application 12886887
Patent Application
App. No. 12/886,887

EXO-S-MECAMYLAMINE FORMULATION AND USE IN TREATMENT

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/886,887
Abstract

A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include but are not limited to substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), aiding smoking cessation, treating weight gain associated with smoking cessation, hypertension, hypertensive crisis, Tourette's Syndrome and other tremors, cancer (such as small cell lung cancer), atherogenic profile, neuropsychiatric disorders (such as bipolar disorder, depression, an anxiety disorder, schizophrenia, a seizure disorder, Parkinson's disease and attention deficit hyperactivity disorder), chronic fatigue syndrome, Crohn's disease, autonomic dysreflexia, and spasmogenic intestinal disorders.

Claims (12)

1 . An oral pharmaceutical composition comprising about 0.5 mg to about 1000 mg of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof substantially free of exo-R-mecamylamine and a pharmaceutically acceptable carrier.

2 . An oral pharmaceutical composition comprising about 1.0 to about 2.5 mg of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof substantially free of exo-R-mecamylamine.

3 . The oral pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is a unit dosage form.

4 . The oral pharmaceutical composition of claim 3 , wherein the unit dosage form is selected from the group consisting of a tablet, capsule, soft gelatin capsule, hard gelatin capsule, powder, lozenge, gum, emulsion, suspension, syrup, and solution.

5 . The oral pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated to provide rapid, sustained, or delayed release of the exo-S-mecamylamine or a pharmaceutically acceptable salt thereof.

6 . The oral pharmaceutical composition of claim 3 , wherein the unit dosage form is administered from one to four times per day.

7 . The oral pharmaceutical composition of claim 3 , wherein the unit dosage form is administered two times per day.

8 . The oral pharmaceutical composition of claim 2 , wherein the pharmaceutical composition is a unit dosage form.

9 . The oral pharmaceutical composition of claim 8 , wherein the unit dosage form is selected from the group consisting of a tablet, capsule, soft gelatin capsule, hard gelatin capsule, powder, lozenge, gum, emulsion, suspension, syrup, and solution.

10 . The oral pharmaceutical composition of claim 2 , wherein the pharmaceutical composition is formulated to provide rapid, sustained, or delayed release of the exo-S-mecamylamine or a pharmaceutically acceptable salt thereof.

11 . The oral pharmaceutical composition of claim 8 , wherein the unit dosage form is administered from one to four times per day.

12 . The oral pharmaceutical composition of claim 8 , wherein the unit dosage form is administered two times per day.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 21, 2011
From: SHYTLE, DOUGLAS; SANBERG, PAUL; NEWMAN, MARY; SILVER, ARCHIE A.
To: UNIVERSITY OF SOUTH FLORDA
Reel/Frame 025836/0961 →